论文部分内容阅读
目的:探讨CD4+ CD25high CD127low调节性T细胞(Regulatory Tcell,Treg)在宫颈癌患者外周血中的表达特点及临床意义。方法:采用流式细胞术检测21例宫颈癌患者和11例健康者外周血中CD4+ CD25high CD127low Treg、CD4+ T细胞、CD8+T细胞和NK细胞的表达水平。结果:21例宫颈癌患者外周血中CD4+ CD25high CD127low Treg占总CD4+ T细胞的(11.17±2.14)%,高于健康对照组(6.96±0.94)%(t=5.974,P<0.05),与NK细胞呈负相关(r=-0.468,P<0.05);CD4+T、CD8+T细胞占总T细胞的比例与健康对照组比较差异均无统计学意义;随疾病进展,宫颈癌患者外周血中CD4+ CD25high CD127low Treg水平升高,Ⅱ期+Ⅲ期患者外周血中CD4+ CD25high CD127low Treg占总CD4+ T细胞的(10.80±1.48)%,明显高于Ⅰ期患者(9.34±1.42)%(P<0.05)和健康对照组(6.96±0.94)%(P<0.05)。结论:宫颈癌患者外周血CD4+ CD25high CD127low Treg表达水平可能是一个较好的反映宫颈癌患者免疫功能状态的参考指标,其在外周血的升高程度与肿瘤临床分期有关,可能参与了宫颈癌的发生发展。
Objective: To investigate the expression of CD4 + CD25high CD127low regulatory T cells (Tregs) in peripheral blood of patients with cervical cancer and its clinical significance. Methods: The expression of CD4 + CD25high CD127low Treg, CD4 + T cells, CD8 + T cells and NK cells in peripheral blood of 21 patients with cervical cancer and 11 healthy controls were detected by flow cytometry. Results: The percentages of CD4 + CD25high CD127low Treg in peripheral blood of 21 patients with cervical cancer were (11.17 ± 2.14)% higher than that of healthy controls (6.96 ± 0.94)% (t = 5.974, P <0.05) (R = -0.468, P <0.05). There was no significant difference in the proportion of CD4 + T and CD8 + T cells in total T cells between healthy controls and control subjects. With the progress of disease, the peripheral blood of patients with cervical cancer CD4 + CD25high CD127low Treg levels in peripheral blood of stage Ⅱ + Ⅲ patients were significantly higher than that of stage Ⅰ patients (9.34 ± 1.42)% (P < 0.05) and healthy control group (6.96 ± 0.94)% (P <0.05). Conclusion: The expression of CD4 + CD25high CD127low Treg in peripheral blood of patients with cervical cancer may be a good reference index to reflect the immune status of patients with cervical cancer. The increase in peripheral blood is related to the clinical stage of cancer and may be involved in the development of cervical cancer Development took place.